Skip to content
Biotech Intelligence

Company Intelligence

Eccogene

益方生物

SH: 688382Shanghai, ChinaFounded 2018
BIOSECURE

No Known BCC Exposure

Eccogene is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure.

1
Tracked Deals
2
Therapeutic Areas
2
Modalities

Overview

Eccogene (益方生物) is a clinical-stage biopharmaceutical company focused on small molecule drug development. Its oral GLP-1 receptor agonist attracted AstraZeneca's attention, resulting in a $1B+ licensing deal that validates Chinese innovation in the global obesity/metabolic drug race. Eccogene's medicinal chemistry capabilities produced a differentiated oral formulation — the industry's "holy grail" in the GLP-1 class.

Key Facts

  • AstraZeneca deal: ~$1B+ for oral GLP-1 receptor agonist — validates Chinese metabolic drug innovation
  • Oral GLP-1 formulation eliminates the injection barrier that limits current semaglutide/tirzepatide adoption
  • Shanghai STAR Market-listed (688382)
  • Focus on small molecule innovation for metabolic and oncology indications

Key Deals

Key licensing and partnership deals for Eccogene.
PartnerDateValueAsset
AstraZeneca2025~$1B+Oral GLP-1 receptor agonist (metabolic)

Corporate Structure

Shanghai STAR Market-listed. Founded by a team with experience from AstraZeneca and other multinational pharma.